Histo-Blood Group Antigen Null Phenotypes Associated With a Decreased Risk of Clinical Rotavirus Vaccine Failure Among Children <2 Years of Age Participating in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in Kenya, Mali, and the Gambia.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
19 04 2023
Historique:
medline: 21 4 2023
pubmed: 19 4 2023
entrez: 19 04 2023
Statut: ppublish

Résumé

Previously studied risk factors for rotavirus vaccine failure have not fully explained reduced rotavirus vaccine effectiveness in low-income settings. We assessed the relationship between histo-blood group antigen (HBGA) phenotypes and clinical rotavirus vaccine failure among children <2 years of age participating in the Vaccine Impact on Diarrhea in Africa Study in 3 sub-Saharan African countries. Saliva was collected and tested for HBGA phenotype in children who received rotavirus vaccine. The association between secretor and Lewis phenotypes and rotavirus vaccine failure was examined overall and by infecting rotavirus genotype using conditional logistic regression in 218 rotavirus-positive cases with moderate-to-severe diarrhea and 297 matched healthy controls. Both nonsecretor and Lewis-negative phenotypes (null phenotypes) were associated with decreased rotavirus vaccine failure across all sites (matched odds ratio, 0.30 [95% confidence interval: 0.16-0.56] or 0.39 [0.25-0.62], respectively]. A similar decrease in risk against rotavirus vaccine failure among null HBGA phenotypes was observed for cases with P[8] and P[4] infection and their matched controls. While we found no statistically significant association between null HBGA phenotypes and vaccine failure among P[6] infections, the matched odds ratio point estimate for Lewis-negative individuals was >4. Our study demonstrated a significant relationship between null HBGA phenotypes and decreased rotavirus vaccine failure in a population with P[8] as the most common infecting genotype. Further studies are needed in populations with a large burden of P[6] rotavirus diarrhea to understand the role of host genetics in reduced rotavirus vaccine effectiveness.

Sections du résumé

BACKGROUND
Previously studied risk factors for rotavirus vaccine failure have not fully explained reduced rotavirus vaccine effectiveness in low-income settings. We assessed the relationship between histo-blood group antigen (HBGA) phenotypes and clinical rotavirus vaccine failure among children <2 years of age participating in the Vaccine Impact on Diarrhea in Africa Study in 3 sub-Saharan African countries.
METHODS
Saliva was collected and tested for HBGA phenotype in children who received rotavirus vaccine. The association between secretor and Lewis phenotypes and rotavirus vaccine failure was examined overall and by infecting rotavirus genotype using conditional logistic regression in 218 rotavirus-positive cases with moderate-to-severe diarrhea and 297 matched healthy controls.
RESULTS
Both nonsecretor and Lewis-negative phenotypes (null phenotypes) were associated with decreased rotavirus vaccine failure across all sites (matched odds ratio, 0.30 [95% confidence interval: 0.16-0.56] or 0.39 [0.25-0.62], respectively]. A similar decrease in risk against rotavirus vaccine failure among null HBGA phenotypes was observed for cases with P[8] and P[4] infection and their matched controls. While we found no statistically significant association between null HBGA phenotypes and vaccine failure among P[6] infections, the matched odds ratio point estimate for Lewis-negative individuals was >4.
CONCLUSIONS
Our study demonstrated a significant relationship between null HBGA phenotypes and decreased rotavirus vaccine failure in a population with P[8] as the most common infecting genotype. Further studies are needed in populations with a large burden of P[6] rotavirus diarrhea to understand the role of host genetics in reduced rotavirus vaccine effectiveness.

Identifiants

pubmed: 37074435
pii: 7130316
doi: 10.1093/cid/ciac910
pmc: PMC10116560
doi:

Substances chimiques

Blood Group Antigens 0
Rotavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

S153-S161

Subventions

Organisme : NIAID NIH HHS
ID : F31 AI126629
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI032042
Pays : United States

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Déclaration de conflit d'intérêts

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Références

Open Forum Infect Dis. 2018 Nov 12;5(11):ofy292
pubmed: 30539038
N Engl J Med. 2010 Jan 28;362(4):289-98
pubmed: 20107214
Expert Rev Vaccines. 2018 Feb;17(2):145-161
pubmed: 29252042
Pediatr Infect Dis J. 2016 Sep;35(9):992-8
pubmed: 27254030
Vaccine. 2012 Apr 27;30 Suppl 1:A24-9
pubmed: 22520132
J Virol. 2012 May;86(9):4833-43
pubmed: 22345472
Sci Rep. 2018 Jan 24;8(1):1502
pubmed: 29367698
Lancet Infect Dis. 2017 Sep;17(9):909-948
pubmed: 28579426
Infect Drug Resist. 2018 Dec 24;12:55-64
pubmed: 30636886
Vaccine. 2012 Apr 27;30 Suppl 1:A52-60
pubmed: 22520137
Lancet. 2013 Jul 20;382(9888):209-22
pubmed: 23680352
Sci Rep. 2018 Aug 28;8(1):12961
pubmed: 30154494
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
J Infect Dis. 2010 Sep 1;202 Suppl:S34-42
pubmed: 20684715
J Infect Dis. 2018 Apr 11;217(9):1399-1407
pubmed: 29390150
JAMA Pediatr. 2018 Oct 1;172(10):958-965
pubmed: 30105384
Lancet. 2010 Aug 21;376(9741):615-23
pubmed: 20692031
J Virol Methods. 2015 Oct;223:96-104
pubmed: 26231786
Nature. 2012 Apr 15;485(7397):256-9
pubmed: 22504179
Lancet. 2014 Jun 21;383(9935):2136-43
pubmed: 24629994
Pathogens. 2017 Dec 12;6(4):
pubmed: 29231855
Sci Rep. 2016 Oct 06;6:34591
pubmed: 27708367
Nat Rev Dis Primers. 2017 Nov 09;3:17083
pubmed: 29119972
Clin Infect Dis. 2012 Dec;55 Suppl 4:S232-45
pubmed: 23169936
Clin Infect Dis. 2019 Sep 27;69(8):1313-1319
pubmed: 30561537
Hum Vaccin Immunother. 2014;10(12):3659-71
pubmed: 25483685
Clin Infect Dis. 2012 Dec;55 Suppl 4:S294-302
pubmed: 23169941
JAMA Pediatr. 2015 Nov;169(11):1040-5
pubmed: 26389824
BMC Infect Dis. 2012 Sep 13;12:213
pubmed: 22974466
Sci Rep. 2017 Jul 25;7(1):6412
pubmed: 28743921
Lancet. 2010 Aug 21;376(9741):606-14
pubmed: 20692030
J Infect Dis. 2017 Mar 1;215(5):786-789
pubmed: 28329092
Sci Rep. 2019 Jul 24;9(1):10764
pubmed: 31341254
J Infect Dis. 2014 Apr 15;209(8):1227-30
pubmed: 24277741
Clin Infect Dis. 2020 May 23;70(11):2298-2305
pubmed: 31326980
J Infect Dis. 2019 Feb 15;219(5):746-749
pubmed: 30357332
Clin Infect Dis. 2014 Dec 1;59(11):1567-73
pubmed: 25097083
Curr Opin Infect Dis. 2019 Oct;32(5):445-452
pubmed: 31335438
Curr Opin Virol. 2012 Aug;2(4):380-8
pubmed: 22789743

Auteurs

Lauren M Schwartz (LM)

Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA.
Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Jennifer Oshinsky (J)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Mardi Reymann (M)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Mathew D Esona (MD)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Michael D Bowen (MD)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

M Jahangir Hossain (M)

Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Syed M A Zaman (SMA)

Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Joquina Chiquita M Jones (JCM)

Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Martin Antonio (M)

Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Henry Badji (H)

Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Golam Sarwar (G)

Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Samba O Sow (SO)

Centre pour le Développement des Vaccins du Mali, Bamako, Mali.

Doh Sanogo (D)

Centre pour le Développement des Vaccins du Mali, Bamako, Mali.

Adama Mamby Keita (AM)

Centre pour le Développement des Vaccins du Mali, Bamako, Mali.

Boubou Tamboura (B)

Centre pour le Développement des Vaccins du Mali, Bamako, Mali.

Awa Traoré (A)

Centre pour le Développement des Vaccins du Mali, Bamako, Mali.

Uma Onwuchekwa (U)

Centre pour le Développement des Vaccins du Mali, Bamako, Mali.

Richard Omore (R)

Kenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.

Jennifer R Verani (JR)

Division of Global Health Protection, US Centers for Disease Control and Prevention, Nairobi, Kenya.

Alex O Awuor (AO)

Kenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.

John B Ochieng (JB)

Kenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.

Jane Juma (J)

Kenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.

Billy Ogwel (B)

Kenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.

Umesh D Parashar (UD)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Jacqueline E Tate (JE)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Irene N Kasumba (IN)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Sharon M Tennant (SM)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Kathleen M Neuzil (KM)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Ali Rowhani-Rahbar (A)

Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA.

M Elizabeth Halloran (M)

Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA.
Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington, USA.
Center for Inference and Dynamics of Infectious Diseases, Seattle, Washington, USA.

Robert L Atmar (RL)

Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

Marcela F Pasetti (MF)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Karen L Kotloff (KL)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH